Glycopyrrolate

Quick Answer

Glycopyrrolate is a quaternary ammonium anticholinergic agent with peripheral muscarinic receptor antagonism, used primarily to counteract muscarinic side effects of anticholinesterases during neuromuscular blockade reversal and as an antisialagogue. Structure: Quaternary ammonium compound (glycopyrronium bromide), charged at physiological pH, limited CNS penetration (does not cross blood-brain barrier well—less CNS effects than atropine). Mechanism: Competitive antagonist at M1, M2, M3 muscarinic receptors (peripheral); reduces salivation, bronchial secretions, gastric acid secretion, increases heart rate (blocks vagal M2 receptors on SA node), relaxes smooth muscle (bronchi, GI tract, bladder). Pharmacokinetics: Poor oral absorption (<10%), IV onset 1-2 minutes, duration 2-4 hours (longer than atropine), renal excretion (unchanged, 65-80%), elimination half-life 0.6-1.2 hours. Dosing: With neostigmine 0.05 mg/kg IV (neostigmine:glycopyrrolate ratio 5:1—0.05 mg/kg neostigmine with 0.01 mg/kg glycopyrrolate), antisialagogue 0.1-0.2 mg IV/IM, intraoperative bradycardia 0.1-0.2 mg IV (repeatable), paediatric antisialagogue 0.01 mg/kg (max 0.2 mg). Advantages over atropine: Does not cross blood-brain barrier (no CNS toxicity, less confusion in elderly), longer duration (matches neostigmine duration better), less tachycardia (more specific for M3 receptors, less M2 cardiac effect), no central anticholinergic syndrome. Side effects: Tachycardia (M2 blockade), dry mouth, reduced secretions (viscous secretions may obstruct airway), urinary retention (bladder detrusor relaxation), constipation (reduced GI motility), ileus, cycloplegia and mydriasis (eye drops—rare with systemic use), hyperthermia (reduced sweating). Contraindications: Narrow-angle glaucoma (pupillary dilation increases IOP), paralytic ileus, severe ulcerative colitis, toxic megacolon, bladder neck obstruction (BPH), myasthenia gravis (worsens condition—unless used with neostigmine for reversal). Clinical use: Routine pairing with neostigmine for neuromuscular reversal (prevents bradycardia, secretions, bronchospasm from neostigmine's muscarinic stimulation), antisialagogue pre-operatively (especially for airway instrumentation, reduces secretions improving visibility), counteracts vagal reflexes (laryngoscopy, surgical manipulation). Comparison to atropine: Glycopyrrolate preferred for neostigmine reversal (better duration match, no CNS effects); atropine preferred for emergency bradycardia (faster onset, CNS effects may be beneficial in cholinergic crisis). [1-10]